Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J. Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do‐Youn Oh; Anke Reinacher‐Schick; Giampaolo Tortora; Hana Algül; Eileen M. O’Reilly; David McGuinness; Karen Cui; Katia Schlienger; Gershon Y. Locker; Hedy L. Kindler

doi:10.1056/nejmoa1903387

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Golan et al. (2019) studied this question.

synapsesocial.com/papers/69d70f295413bc3de5ab3519 https://doi.org/10.1056/nejmoa1903387

View Full Paper

Ask AI

Bookmark

Share

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading